Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth
Company Boasts 51 Late-Stage Candidates
Pharma chief Bill Anderson was optimistic about growth prospects, and downplayed Roche’s reliance on two near-term readouts at an investor day in London.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: a big US approval for BMS; Roche touts its diverse R&D pipeline; Lumakras’s mixed Phase III results in lung cancer; Japan controversy over a COVID-19 antiviral; and GSK's vaccine strategy in India.
Amgen secured a last-minute slot as a late-breaker study with Lumakras, appearing to give it the upper hand on rival Mirati once again.
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.